Analysts in India see potential for slowdown of generic approvals by U.S.

10/4/2013 | Times of India, The

India's domestic pharmaceutical industry could be affected by the U.S. government shutdown if it persists. The shutdown could delay approvals of new generic drugs, which are the growth drivers of domestic drugmakers' operating margins and revenues, analysts said. The U.S. FDA's monitoring and progress on recent actions could be delayed.

View Full Article in:

Times of India, The

Published in Briefs: